Background. During primary infection, human herpesvirus-6 (HHV-6) may become integrated into the chromosome. This entity, termed chromosomally integrated HHV-6 (CIHHV-6), is often mistaken as active infection and treated unnecessarily. The prevalence of CIHHV-6 in kidney transplant recipients is not known. Methods. We performed quantitative HHV-6 polymerase chain reaction assay on whole blood samples collected from 47 kidney recipients. CIHHV-6 was defined as HHV-6 DNA levels >1 × 10 6 genomes/mL. Results. One of 47 kidney recipients was found to have CIHHV-6. The prevalence of CIHHV-6 was calculated at 2.1% (95% confidence interval, <0.01-12.1%). Despite an increase in HHV-6 DNA level after transplant, the patient did not develop clinical HHV-6 disease.
Introduction
Instead of existing as a separate circular DNA, human herpesvirus 6 (HHV-6) may become integrated into the host chromosome. This is known as chromosomally integrated HHV-6 (CIHHV-6). Both variants HHV-6A and HHV-6B have the ability to integrate into the chromosome [1] . Because they are found in germ lines, CIHHV-6 may be transmitted vertically from mother to child [2, 3] . As a consequence of the presence of the viral genome in every nucleated cell, patients with CIHHV-6 have very high baseline levels of the virus in blood and tissues [4] .
The clinical significance of CIHHV-6 is not known, and there is very limited data on its prevalence after transplantation [5] . Because transplant patients may have their blood tested for HHV-6 during evaluation of various clinical syndromes, CIHHV-6, which exists as high HHV-6 levels in blood, may be misinterpreted as 'active' viral infection. This may lead to unnecessary treatment with potentially toxic drugs, without further evaluation of the true underlying etiology of the clinical illness [1] . Herein, we report the prevalence of CIHHV-6 in kidney recipients in order to increase the awareness of this entity among clinicians.
Patients and methods

Study population
The population consisted of 47 kidney recipients who participated in a clinical study of cytomegalovirus-specific immunity [6] . Peripheral whole blood samples were obtained prior to transplantation, at week 2, during months 1-3, months 4-6 and at month 12 after transplantation. These samples have been stored at −80°C prior to this study. Posttransplant care was described previously [6] . All patients received valganciclovir prophylaxis (900 mg once daily, renally dose adjusted) for 90 days. The study was approved by the Institutional Review Board of Mayo Foundation.
Definitions and detection of CIHHV-6
CIHHV-6 was defined as HHV-6 DNA levels >1 × 10 6 genomes/mL of whole blood [7] ; this definition is recommended in the absence of hair follicle or molecular cytogenetic analysis. To determine CIHHV-6, whole blood samples were tested for HHV-6 using real-time quantitative polymerase chain reaction (LightCycler; Roche Diagnostics, Indianapolis, IN). Whole blood sample is recommended since HHV-6 is a cell-associated virus, although use of noncellular samples such as plasma may also detect the virus, albeit at a much lower level. Detection was carried out as follows: initial denaturation at 95°C for 10 min, followed by 45 cycles of denaturation (95°C for 10 s, at a slope of 20°C/s), annealing (55°C for 15 s) and extension (72°C for 15 s). HHV-6 variants were differentiated based on LightCycler melting curve analysis. HHV-6A had a melting peak at 72°C, while HHV-6B had a melting peak at 66°C [8] . The complete medical records of the 47 patients were reviewed. Table 1 shows demographic and clinical characteristics of the patients.
Results
HHV-6 DNA was quantified from 130 whole blood samples from the 47 patients. The median number (range) of samples per patient was 3 (1-5). Only one patient had CIHHV-6 (variant B). The prevalence of CIHHV-6 was calculated at 2.1% [95% confidence interval (CI), <0.01-12.1%]. Another patient had pretransplant HHV-6 load of 463 genomes/mL; this patient had no clinical symptoms or signs of viral infection, and her HHV-6 load was undetectable at 2 weeks and 4 months after transplantation.
CIHHV-6 was detected in a 40-year-old Caucasian male who had living donor kidney transplant for systemic oxalosis. He was cytomegalovirus D+/R+ and received valganciclovir (900 mg daily) prophylaxis for 90 days. His baseline HHV-6 level was 5.1 × 10 6 genomes/mL (corresponding WBC count, 6700/mm 3 ) prior to transplant, and this increased to 22.5 × 10 6 /mL (WBC, 7900/mm 3 ) 2 weeks after transplantation despite on valganciclovir. No further samples were available for testing. Three months after transplantation, he developed severe edema of upper and lower extremities associated with acute renal failure and thrombosis of the left axillary vein. His serum creatinine increased to 2.3 mg/dL from a baseline of 1.3-1.4 mg/dL. Renal allograft biopsy did not show rejection or crystal deposition. He had erythematous facial rashes thought to be seborrheic dermatitis. He did not have any febrile illness. One week later, he developed bilateral visual impairment and a complete motor paralysis of his lower extremities. MRI revealed poorly enhancing optic chiasmal syndrome and a nonenhancing signal that extended from T8 spinal cord through the conus. These neurologic findings were assessed to be due to embolic etiology. Cerebrospinal fluid analysis was normal. He died 4 weeks later due to sudden symptomatic bradycardia, which rapidly progressed to pulseless electrical activity.
Discussion
Based on the study of healthy blood donors [7] , the prevalence of CIHHV-6 is 0.8% (95% CI, 0.2-2.1%). There is limited data on the prevalence of CIHHV-6 in the transplant population. In two prior studies, three (5%; 95% CI, 1.2-14.3%) of 60 liver [9] and one (1.9%; 95% CI, <0.01-11.1%) of 52 kidney recipients had HHV-6 loads >1 × 10 6 genomes/mL of whole blood [10] and could be assumed to have had CIHHV-6. In a recent study of 205 transplant patients, the prevalence of CIHHV-6 was 1.0% (95% CI, 0.5-3.5%) [5] . In this third study, one (1.4%; 95% CI, <0.01-8.4%) of 70 hematopoietic stem cell and one (0.7%; 95% CI, <0.01-4.5%) of 135 solid organ transplant recipients had CIHHV-6 [5] . Our study is consistent with these reports since we observed the prevalence of CIHHV-6 in kidney recipients at 2.1% (95% CI, <0.01-12.1%).
There are nine publications describing 12 cases of CIHHV-6 after transplantation (11 after hematopoietic stem cell and 1 after small bowel transplantation) [5, [11] [12] [13] [14] [15] [16] [17] [18] . None of 13 patients, including our case, with CIHHV-6 developed definite HHV-6 disease after transplantation. Our case had skin rash and neurologic manifestations, which are typical manifestations of HHV-6 disease; however, these were clinically diagnosed as seborrheic dermatitis and embolic phenomenon, respectively. In addition, CSF analysis was normal, while patients with HHV-6 encephalitis typically have lymphocytic pleocytosis. In four previously reported patients with high HHV-6 levels, antiviral therapy with ganciclovir, valganciclovir, foscarnet or cidofovir was used despite lack of symptoms [12, [15] [16] [17] [18] , but these did not result in reducing HHV-6 levels. In our patient, HHV-6 load increased at 2 weeks, potentially signifying HHV6 reactivation despite valganciclovir prophylaxis, but there were no symptoms related to the viral illness.
In summary, this study defines the prevalence of CIHHV-6 in kidney recipients at 2.1%. Our review of our case and those of the literature demonstrates that patients with CIHHV-6 may not develop active clinical HHV-6 disease despite high baseline viral loads. Clinicians should be aware of this entity of CIHHV-6 so that misdiagnosis and unnecessary treatment can be avoided. 
